drugset / Trial / NCT05766371
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
Phase 2
Recruiting
48 enrolled
University of California, San Francisco
Merck Sharp & Dohme LLC · collabProstate Cancer Foundation · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, open-label, study of Prostate-Specific Membrane Antigen (PSMA)-targeted radionuclide therapy with 177Lu-PSMA-617 in combination with pembrolizumab in participants with metastatic castrate-resistant prostate cancer (mCRPC) who have previously progressed on at least one prior androgen pathway inhibitor (e.g., abiraterone, enzalutamide, apalutamide).
Timeline
- Start
- 2023-12-15
- Primary completion
- 2027-05-31
- Completion
- 2031-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu-PSMA-617 | Other / unclassified | 7400 mbq | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 400 mg | Intravenous |